Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Intellia rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Analyst Ratings for Intellia Therapeutics

Analyst Ratings for Intellia Therapeutics

Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings for Intellia Therapeutics

Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Intellia Therapeutics: Q1 Earnings Insights

Intellia Therapeutics (NASDAQ:NTLA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Preview For Intellia Therapeutics

Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Intellia Therapeutics will report an earnings per share (EPS) of $-1.10.

How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call

Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

4 Analysts Have This to Say About Intellia Therapeutics

4 Analysts Have This to Say About Intellia Therapeutics

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:

Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today

Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis.

$100 Invested In This Stock 5 Years Ago, Would Be Worth This Much

$100 Invested In This Stock 5 Years Ago, Would Be Worth This Much

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 33.15% on an annualized basis.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

Western Digital

Micron Technology

Archer Aviation

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play